Lung Cancer Proteomics: Investigating Volatile Biomarkers with Tools

This report details a study design leveraging proteomics tools to investigate volatile biomarkers of lung cancer. It addresses the limitations of relying solely on mRNA levels for gene expression analysis and emphasizes the importance of proteomic analysis for understanding protein functionality. The study design covers sample preparation techniques, including LCM and imaging MS, to ensure accurate representation of cancer cell populations. It also discusses fractionation methods like DOC-TCA precipitation for protein extraction and purification, as well as advanced analytical techniques such as microLC-MS/MS and SPME/GC-MS for biomarker identification. Furthermore, the report explores bioinformatics analysis methods for identifying tumor antigens and autoantibodies, highlighting the potential for early cancer detection and treatment strategies. The study aims to provide a comprehensive dataset for lung cancer research by integrating proteomics, mass spectrometry, and bioinformatics, offering insights into potential diagnostic and therapeutic targets. Desklib provides access to similar documents and AI study tools.

Running head: PROTEOMICS
PROTEOMICS
Name of the Student:
Name of the University:
Author Note:

1PROTEOMICS
Title
Use of proteomic tools for investigation of volatile biomarkers of lung cancer
Abstract
Lung cancer is one of the most devastating diseases. In the case of lung cancer gene
expression relationship is generally occurs at the mRNA level, while at the corresponding protein
level, the expression is quite complex. Therefore using proteomics the determination of the
tridimensional structure of molecules is carried out and it allows obtaining a specific image of
the proteins that are functional in the cell. The proteome is referred as the total number of
proteins that is expressed by a specific cell in a given time. This paper highlights the direct
separation and quantification of the proteome of human lung cancer cells and for establishing a
screening of a biomarker of the disease. The paper also elaborates the method of sample
preparation along with fractionation of the sample proteins with bioinformatics analysis and
mass spectra analysis.
Introduction
On one of the leading causes of death in males on a worldwide basis is lung cancer. It is
also the second largest cause of death in the female population. This is mainly due to cigarette
smoking that leads to a dose-response relationship especially in males, accounting for almost
90% and in females it accounts to about 70% (Gregorc et al. 2014). Even after quitting cigarette,
there is an incidence of regression. This incidence of dose-response has been perceived in there

2PROTEOMICS
major types of lung cancer that involves small cell, squamous cell and adenocarcinoma. In the
case of lung cancer, gene expression relationship is generally occurs at the mRNA level, while at
the corresponding protein level, the expression is quite complex (Pastor et al. 2013). However
the expression co-efficient of the mRNA/protein correlation, varies among the proteins having
multiple isoforms. This indicates significant separate isoform-specific mechanisms implemented
to regulate the abundance of protein. For such cases, there is a need for translational studies that
combines the transriptomes with the proteomics tools (Cardnell et al. 2013). Using proteomics,
the determination of the tridimensional structure of molecules is carried out and it allows
obtaininga specific image of the functional proteins in the cell. The proteome is referred as the
total number of proteins that is expressed by a specific cell in a given time.This paper highlights
the direct separation and quantification of the proteome of human lung cancer cells and for
establishing a screening of a biomarker of the disease. The paper also elaborates the method of
sample preparation along with fractionation of the sample proteins with bioinformatics analysis
and mass spectra analysis.
Sample preparation
Adequate sample selection as well as preparation forms the basis of the quality and the
reproducibility of the proteomic and translational studies. In the context of lung cancer, the
proteomic studies are conducted using the biopsies of the whole tissues. The accuracy of the
results are dependent on the amount of the cell populations including the epithelial, endothelial
and the inflammatory cells (Shaw et al. 2013). In order to conduct the proteomic studies there is
a requirement for large amount of samples in order to ensure that that the risk of analyzing
normal cells mixed with the pathological cells along with the stromal cells and connective tissue

3PROTEOMICS
which is not underestimated. For preparation of samples techniques like LCM or purification of
epithelial cells using antibody-coated magnetic beads is used. Another method that is often
applied is the direct evaluation of the tissues of the lung proteome using imaging MS (Indovina
et al. 2013). This method involves MALDI-TOF MS which can be applied in a direct manner to
1-mm regions of the frozen tissue section. This can be implemented by protein expression
profiling in the 79 lung tumors along with the 14 normal lung tissues. Through this more than
1600 protein peaks can be obtained (Yu et al. 2014). This predictive model can be applied to a
cohort test that is masked and includes 37 lung tumors and 6 normal lung samples. This model
nearly perfectly classified samples in the independent blinded test cohort (Alberg et al. 2013).
Fractionation of the sample proteins
After the samples are obtained the cells or tissue substance need to be completely
solubilized for extracting a pool of therepresenative proteome. A critical problem is represented
in the extraction of the film proteins to a specific test in proteomics inquire about, because of
their low dissolvability (Park et al. 2013). In lung cancer, enhanced deoxycholatetrichloroaetic
corrosive (DOC-TCA) precipitation can be utilized to extricate and sanitize the aggregate
proteins of bronchial epithelial examples. At the point when 2DPAGE was repeated for three
times, with the normal coordinating rate being 89.3% and protein spots in the three gels might
show a decent reproducibility (Rolfo et al. 2014). The normal position deviation of coordinated
spots in various gels was low in the first (isoelectric centering) as well as in the second [sodium
dodecyl sulfate (SDS)– PAGE] course. The enhanced DOC-TCA precipitation gives off an
impression of being so far the main technique for protein test readiness that has been particularly
tried in bronchial epithelial tissues (Sun et al. 2015).

4PROTEOMICS
The proteomics technologies were additionally connected for the investigation of body
liquids in lung tumor patients, specifically for the examination of plasma, serum pleural
emanations. Plasma is the highest source of proteins in the human body, and is additionally one
of the least demanding to gather, prompting its expansive use in proteomics look into and in
addition in clinical diagnostics (Győrffy et al. 2013). However, the plasma proteome is likewise
the most troublesome variant of the human proteome: low abundant biomarkers are clouded by
the nearness of pervasive proteins—the 10 lowest proteins in plasma represent around 90% of
the aggregate proteome. In addition the protein substance of body liquids is affected by countless
variables, for example, protein turnover, weakening, oxydation or corruption and, in pleural
radiations, by the inundation of plasma proteins (Gregorc et al. 2014).
If there should be an occurrence of serum protein examination, Gradient polyacrylamide
gel (SDS– PAGE) was connected to research if serum proteins design is fit to separate lung
disease patients from solid people. Serum tests acquired from 66 lung growth patients and from
44 sound contributors were thought about, and distinctive proteins groups were found with
expanded recurrence and additionally force in the two patients and controls (van Bon et al.
2014). It was seen that the peptides of importance were not distinguished. Novel advances, for
example, SELDI TOF MS ProteinChip framework and other protein exhibits are presently
accessible and have helped serum protein investigation. In lung growth, a sum of 208 serum
tests, including 158 lung disease patients and 50 sound people, were dissected by SELDI
innovation (Indovina et al. 2013). Five protein tops were consequently picked as a biomarker
design in a preparation set and, when the peptide design was tried with the blinded test set, it
yielded an affectability of 87%. These first outcomes recommended that serum SELDI protein
profiling can recognize lung disease patients, particularly NSCLC patients, from ordinary

5PROTEOMICS
subjects with moderately high affectability and specificity. Be that as it may, the personality of
the pinnacles of intrigue has not been distributed up until this point. In another examination
including 28 serum tests from patients with NSCLC and 12 from ordinary people, two
biomarkers were up-directed while three biomarkers were down-controlled in the serum tests
from NSCLC patients (Kadoch et al. 2013). This finding is inventive as it would infer that
growth may be identified by the nonattendance of honest to goodness proteins—the inverse of
tumor-related antigens. Examination of serum proteins in lung disease is additionally
conceivable without gel detachment, by coupling for instance a two-dimensional microflow fluid
chromatography with a pair MS (2D microLC-MS/MS) (Wood et al. 2015).
Analysis by mass spectrophotometry (MS)
A research group proposed to incorporate a direct particle trap mass spectrometer into the
microLC-MS/MS framework in order to obtain the end goal to get exceedingly enhanced
affectability and objective in mass spectrophotometer or mass spectrophotometer securing and
investigated the proteome of the immunoglobulin-drained plasma tests from solid people and
lung adenocarcinoma patients. More than 100 unique proteins could be distinguished, and
protein identification of the datasets of both sound and adenocarcinoma bunches uncovered that
few proteins could be applicant diseases markers (Ummanni et al. 2014).
A new approach which issimilar comparable approach could be connected solid phase
microextraction (SPME) and gas chromatography-MS (GC-MS) for examination of lung disease
unstable biomarkers. The headspace SPME conditions including the fiber covering along with
the temperature of extraction in addition to the time of extraction and desorption conditions
which were enhanced and connected to assurance of volatiles in human blood (Li et al. 2014). To

6PROTEOMICS
discover the biomarkers of lung malignancy, unpredictable mixes were explored in blood of lung
disease patients and controls. Blood concentration of hexanal and heptanal in patients with lung
cancer was observed to be significantly higher than those present in controls. These primer
outcomes demonstrate that SPME/GC-MS may be a technique appropriate for examination of
unpredictable lung growth markers in human blood (Byers and Rudin 2015).
This technique will address the limitations by finding the biomarkers of lung cancer and
by will try to investigate the volatile compounds present in lung cancer blood. A control was
conducted by using the given method. The concentrations of hexanal and heptanal in lung cancer
blood were seen to be quite highin comparison to control blood. Similarly the hexanal and
heptanal were rconsidered as biomarkers of lung cancer. By comparing te volatiles in breath and
in blood, it was shown that hexanal and heptanal in breath were originated from blood and
similarly in screening of lung cancer by breath analysis. These results showed that SPME/GC-
MS is a simple as well as a rapid and sensitive method which is very suitable for detection of
volatile disease markers in human blood in comparison to traditional methods.
Bioinformatics analysis of the tumor biomarkers
The identification of coursing tumor antigens or their related auto antibodies gives a way
to early growth finding and leads for treatment. Research over the previous years has brought
about a few reports on the nearness of autoantibodies against illness related proteins, for
example, annexins I and II, recoverin and protein quality item 9.5 in the sera of patients with
lung growth (Mehan et al. 2014). Comparsion of 2D-PAGE/Western smear/electrochemi-
radiance (ECL) discovery uncovered particular circulations of antibodies in the sera of lung
adenocarcinoma, tuberculosis and solid subjects and permitted the identification of 16 protein

7PROTEOMICS
spots in disease patients that included alpha enolase and thechaperonin(Cancer Genome Atlas
Research Network 2014). A counter acting agent against alpha-enolase was seen in three of five
patients having adenocarcinoma (Ahn et al. 2014).
A total bioinformatics evaluation can be completed with a specific end goal to identify
the mutational frequencies of the lung tumor cells. Endeavors to distinguish biomarker complex
segments have for the most part utilized overexpressed, labeled proteins in changed cell lines,
which aggravate stoichiometric connections (Franchina et al. 2014). The investigations carried
out in most of the studies revealed that the bioinformatic studies enables the researchers to
precisely decide the subunit piece of endogenous biomarker ccomplexes, uncovering a few new
subunits and in addition associating proteins without the committed, non-interchangeable
highlights of a subunit. It was seen that the biomarker buildings have roughly indistinguishable
steadiness from the ribosome utilizing urea-based denaturation techniques (Vargas and
Harris2016). Thus, the capacity of the recognized biomarkers were like set up subunits, ought to
be considered with regards to biomarker complex capacity. However these subunits and also
annexins I and II, recoverin and protein quality item are absent in the biomarker complex
(Taverna et al. 2016). In this way, it was likely play some role in the capacity identified with
development of more up to date techniques of chromatin direction, for example, more prominent
multifaceted nature/specificity in biomarker complex focusing on, polycomb-intervened
constraint, or DNA methylation. These distinctions contrasted with lung growth biomarkers
drove us to conclude to the structures as annexins as opposed to recoverin to forestall unseemly
extrapolation (Cardnell et al. 2013). Here it was utilized this as per normal use. The proteomic
insights enabled a complete examination of tumor change frequencies in tumors from 44 entire
genome and exome sequencing thinks about. The buildings were transformed over the biomarker

8PROTEOMICS
of lung cancer studies, which spread over a wide range of strong and hematologic tumors.
However, it has been perceived that the likewise tumor composes in which biomarker is as often
as possible transformed, however does not achieve hugeness because of deficient quantities of
patients and hypermutation (Pastor et al. 2013).
Conclusion
Proteomics advancements are progressively connected in translational lung cancer
research. In spite of the fact that they are not being used for long and encouraging outcomes,
however they have just been accomplished in the analytic, prognostic and in addition in the
remedial regions. Proteomics is a quickly advancing field with the novel advancements,
specifically with innovative changes. The study shows that without gel mass spectrophotometer,
there is an additional of the ongoing production of the primary consequences of the collective
exertion of the Human Plasma Proteome Project. This might lead to the increment of the pace of
research in the coming years. With careful sample preparation there is an example arrangement
strategie along with the examination of adequate quantities of tests with making an interpretation
of mechanical advancement into helpful analytic and restorative devices. The use of proteomics
use is a valuable supplement to histopathology to explain the components that decide clinical
phenotype. This study showed that SPME with GC–MS is a simple and fast method along with a
sensitive and solvent-free method which is appropriate for evaluation of volatile compounds in
human blood. Using this particular method, hexanal and heptanal were detected in lung cancer
blood easiliycompatred to the other methods. The results successfully show that hexanal and
heptanal in blood were regarded as biomarkers of lung cancer. Through the comparison of
volatile compounds in breath and in blood, it was shown that hexanal and heptanal in breath

9PROTEOMICS
were originated from blood and hexanal and heptanal and screening of lung cancer by breath
analysis is obtainable.
References
Ahn, J.M., Sung, H.J., Yoon, Y.H., Kim, B.G., Yang, W.S., Lee, C., Park, H.M., Kim, B.J., Kim,
B.G., Lee, S.Y. and An, H.J., 2014. Integrated glycoproteomics demonstrates fucosylated serum
paraoxonase 1 alterations in small cell lung cancer. Molecular & Cellular Proteomics, 13(1),
pp.30-48.
Alberg, A.J., Brock, M.V., Ford, J.G., Samet, J.M. and Spivack, S.D., 2013. Epidemiology of
lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians
evidence-based clinical practice guidelines. Chest, 143(5), pp.e1S-e29S.
Byers, L.A. and Rudin, C.M., 2015. Small cell lung cancer: where do we go from
here?. Cancer, 121(5), pp.664-672.
Cancer Genome Atlas Research Network, 2014. Comprehensive molecular profiling of lung
adenocarcinoma. Nature, 511(7511), p.543.
Cardnell, R.J., Feng, Y., Diao, L., Fan, Y.H., Masrorpour, F., Wang, J., Shen, Y., Mills, G.B.,
Minna, J.D., Heymach, J.V. and Byers, L.A., 2013. Proteomic markers of DNA repair and PI3K

10PROTEOMICS
pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung
cancer. Clinical cancer research, pp.clincanres-1975.
Franchina, T., Amodeo, V., Bronte, G., Savio, G., Ricciardi, G.R., Picciotto, M., Russo, A.,
Giordano, A. and Adamo, V., 2014. Circulating miR‐22, miR‐24 and miR‐34a as novel
predictive biomarkers to pemetrexed‐based chemotherapy in advanced non‐small cell lung
cancer. Journal of cellular physiology, 229(1), pp.97-99.
Gregorc, V., Novello, S., Lazzari, C., Barni, S., Aieta, M., Mencoboni, M., Grossi, F., De Pas,
T., De Marinis, F., Bearz, A. and Floriani, I., 2014. Predictive value of a proteomic signature in
patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy
(PROSE): a biomarker-stratified, randomised phase 3 trial. The lancet oncology, 15(7), pp.713-
721.
Gregorc, V., Novello, S., Lazzari, C., Barni, S., Aieta, M., Mencoboni, M., Grossi, F., De Pas,
T., De Marinis, F., Bearz, A. and Floriani, I., 2014. Predictive value of a proteomic signature in
patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy
(PROSE): a biomarker-stratified, randomised phase 3 trial. The lancet oncology, 15(7), pp.713-
721.
Győrffy, B., Surowiak, P., Budczies, J. and Lánczky, A., 2013. Online survival analysis software
to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung
cancer. PloS one, 8(12), p.e82241.
Indovina, P., Marcelli, E., Pentimalli, F., Tanganelli, P., Tarro, G. and Giordano, A., 2013. Mass
spectrometry‐based proteomics: The road to lung cancer biomarker discovery. Mass
spectrometry reviews, 32(2), pp.129-142.

11PROTEOMICS
Indovina, P., Marcelli, E., Pentimalli, F., Tanganelli, P., Tarro, G. and Giordano, A., 2013. Mass
spectrometry‐based proteomics: The road to lung cancer biomarker discovery. Mass
spectrometry reviews, 32(2), pp.129-142.
Kadoch, C., Hargreaves, D.C., Hodges, C., Elias, L., Ho, L., Ranish, J. and Crabtree, G.R., 2013.
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive
roles in human malignancy. Nature genetics, 45(6), p.592.
Li, L., Wei, Y., To, C., Zhu, C.Q., Tong, J., Pham, N.A., Taylor, P., Ignatchenko, V.,
Ignatchenko, A., Zhang, W. and Wang, D., 2014. Integrated omic analysis of lung cancer reveals
metabolism proteome signatures with prognostic impact. Nature communications, 5, p.5469.
Mehan, M.R., Williams, S.A., Siegfried, J.M., Bigbee, W.L., Weissfeld, J.L., Wilson, D.O., Pass,
H.I., Rom, W.N., Muley, T., Meister, M. and Franklin, W., 2014. Validation of a blood protein
signature for non-small cell lung cancer. Clinical proteomics, 11(1), p.32.
Park, J.O., Choi, D.Y., Choi, D.S., Kim, H.J., Kang, J.W., Jung, J.H., Lee, J.H., Kim, J.,
Freeman, M.R., Lee, K.Y. and Gho, Y.S., 2013. Identification and characterization of proteins
isolated from microvesicles derived from human lung cancer pleural
effusions. Proteomics, 13(14), pp.2125-2134.
Pastor, M.D., Nogal, A., Molina-Pinelo, S., Melendez, R., Salinas, A., De la Pena, M.G., Martin-
Juan, J., Corral, J., García-Carbonero, R., Carnero, A. and Paz-Ares, L., 2013. Identification of
proteomic signatures associated with lung cancer and COPD. Journal of proteomics, 89, pp.227-
237.